Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 609-618

  Kuehn, Thorsten ^a   Bauerfeind, Ingo ^b   Fehm, Tanja ^c   Fleige, Barbara ^d   Hausschild, Maik ^e   Helms, Gisela ^f   Lebeau, Annette ^g   Liedtke, Cornelia ^h   Minckwitz, Gunter von ^i,j   Nekljudova, Valentina ⁱ   Schmatloch, Sabine ^k   Schrenk, Peter ^l   Staebler, Annette ^f   Untch, Michael ^d  

^a KLINIKUM ESSLINGEN   (Germany)

^b Klinikum Landshut   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e Spital Rheinfelden   (Switzerland)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ German Breast Group   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k Elisabeth Krankenhaus Kassel   (Germany)

^l KEPLER UNIVERSITY HOSPITAL   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE;

ADULT; AGED; ARTICLE; AUSTRIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; GERMANY; HUMAN; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FALSE NEGATIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; YOUNG ADULT;

EID: 84878349939     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70166-9     Document Type: Article

References (28)

1. Kim T, Giulliano AE, Lyman GH Lymphatic mapping and sentinel lymph node biopsy in early stage breast carcinoma: a metaanalysis. Cancer 2006, 106:4-16.
2. Haid A, Kuehn T, Konstantiniuk P, et al. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 2002, 28:705-710.
3. Helms G, Kühn T, Moser L, Remmel E, Kreienberg R Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection: data from a prospective randomised trial. Eur J Surg Oncol 2009, 35:697-701.
4. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, 2006. Ann Oncol 2007, 18:1927-1934.
5. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
6. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999, 230:72-78.
7. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 phase III trial. Lancet Oncol 2007, 8:881-888. for the National Surgical Adjuvant Breast and Bowel Project (NSABP).
8. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11:927-933.
9. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002, 20:1304-1310.
10. Smith BD Using chemotherapy response to personalise choices regarding locoregional therapy: a new era in breast cancer treatment?. J Clin Oncol 2012, 30:3913-3914.
11. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006, 93:539-546.
12. Kelly AM, Dwamena B, Cronin P, Carlos RC Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta analysis. Acad Radiol 2009, 16:551-563.
13. Van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 2009, 45:3124-3130.
14. Lee S, Kim EY, Kang SH, et al. Sentinel node identification rate, but not accuracy, is significantly decreased after preoperative chemotherapy in axillary node-positive patients. Breast Cancer Res Treat 2007, 102:283-288.
15. Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 2007, 14:2946-2952.
16. Le Bouëdec G, Geissler B, Gimbergues P, et al. Sentinel lymph node biopsy for breast cancer after neoadjuvant chemotherapy: influence of nodal status before treatment. Bull Cancer 2006, 93:415-419. [in French].
17. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007, 109:1255-1263.
18. Takahashi M, Jinno H, Hayashida T, Sakata M, Asakura K, Kitagawa Y Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg 2012, 36:2847-2852.
19. Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 2012, 19:3177-3184.
20. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009, 27:726-732.
21. Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol 2005, 12:697-704.
22. Kuehn T, Bembenek A, Decker T, et al. A concept for the clinical implementation of sentinel lymph node biopsy (SLNB) in breast cancer patients with special regard to quality assurance. Cancer 2005, 103:451-461. for the Consensus Committee of the German Society of Senology.
23. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol 2005, 23:7703-7720.
24. Sobin L, Gospodarowicz M, Wittekind C UICC TNM classification of malignant tumours 2009, Wiley-Liss, New York. 7th edn.
25. Kuehn T, Vogl FD, Helms G, et al. Sentinel-node-biopsy is a reliable method for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004, 30:252-256.
26. Boughey JC, Suman VJ, Mittendorf EA, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 trial. Cancer Res 2012, 72(24 suppl). abstr 94s.
27. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from NSABP protocol B-27. J Clin Oncol 2005, 23:2694-2702.
28. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg 2010, 252:426-433.